Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics to Present at the 2016 Wells Fargo Healthcare Conference
AUSTIN, Texas , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare disease and cancer, today announced that its chief executive officer, David G.
Toggle Summary Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies
Company Expands Profile of AEB1102 into Second Cancer Type AUSTIN, Texas , Aug. 29, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer,
Toggle Summary Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results
AUSTIN, Texas , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare diseases and cancer, today reported financial results for the quarter ended
Toggle Summary Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer
--EMA Issued a Positive Opinion for Orphan Drug Designation for AEB1102-- --Initiated Two Phase 1 Clinical Trials of AEB1102 for Treatment of Hyperargininaemia and Hematological Malignancies-- AUSTIN, Texas , July 18, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency
AUSTIN, Texas , May 23, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced it received Fast Track
Toggle Summary Aeglea BioTherapeutics To Present at the UBS 2016 Global Healthcare Conference
AUSTIN, Texas , May 20, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that management will be
Toggle Summary Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results
AUSTIN, Texas , May 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today reported financial results for the
Toggle Summary Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer
AUSTIN, Texas , May 16, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced it has named Sandra
Toggle Summary Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas , April 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that it will present in a
Toggle Summary Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas, April 18, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced that it will present in a
Toggle Summary Aeglea BioTherapeutics Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option
AUSTIN, Texas , April 12, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the closing of its initial
Toggle Summary Aeglea BioTherapeutics Announces Pricing of Initial Public Offering
AUSTIN, Texas --(BUSINESS WIRE)--Apr. 7, 2016-- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial
Toggle Summary Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Anthony Quinn, M.B Ch.B, Ph.D., FRCP to
Toggle Summary Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies
--Planned Phase 1 Study to Enroll Patients with Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome -- AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid
Toggle Summary Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency
Austin, Texas (January 07, 2016) – Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the U.S.